drugset / Trial / NCT06286098

Alpha Lipoic Acid in Pediatrics on Hemodialysis

NCT06286098

Phase 3 Enrolling by invitation 50 enrolled Ain Shams University Eva Pharma · collab
RandomizedParallel-groupDouble-blindSupportive care

Summary

The goal of this clinical trial is to test alpha lipoic acid in children undergoing hemodialysis. The main questions it aims to answer are: * Will the use of alpha lipoic acid lower cardiovascular events in that population? * Is the incidence of those cardiovascular events linked to the oxidative stress and endothelial dysfunction in that population? * Will the drug cause side effects? Participants will: * take either one dose daily of 600mg tablet Alpha lipoic acid orally or a look-alike tablet containing no drug. * be monitored for the occurrence of cardiovascular events (stroke, angina, etc.) * be monitored for the occurrence of side effects * give blood samples for testing serum levels of E-selectin biomarker and superoxide dismutase enzyme * undergo clinical examinations (Echocardiogram, Duplex ultrasonography, Intima-Media-Thickness) Researchers will compare between the group taking alpha lipoic acid and the group taking the look-alike tablet.

Timeline

Start
2025-02-02
Primary completion
2027-11-30
Completion
2028-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject alpha-lipoic acid Small molecule 600 mg Oral

Indications